| 저자 |
Hye Sook Min1, Sung Jin Kim1, Jung Eun Kim1, Jung Yeon Chee1,Hyun Wook Kim2, Ji Eun Lee2, Dae Ryong Cha1, Young Sun Kang1 |
| 초록 |
Introduction: Adiponectin regulates the metabolism of lipids and glucose. And it plays important role in the development of insulin resistance and atherosclerosis. However, it is uncertain that the association of adiponectin with diabetic complications. We investigated the association of serum adiponectin level with diabetic complications in type 2 diabetic patients.
Methods: We conducted a prospective study of 161 patients with type 2 diabetes from 2002 to 2013. Spearman’s correlation coefficients were calculated to evaluate the relationship between adiponectin and biomarkers associated with diabetic complications. To assess the linear by linear association between adiponectin and diabetic complications, score test for trend was performed with grouping each adiponectin and biomarkers. All statistical analyses were performed using SPSS version 18.0.
Results: Age, sex, DM duration, cholesterol, LDLcholesterol, calcium channel blocker, thiazolidinedione neuropathy, dialysis and 24hr protein efficiency ratio were positively correlated with serum adiponectin level (all p<0.05). And eGFR were negatively correlated with serum adiponectin level (all p<0.05). Adiponectin was significantly linear increased with age, sex, smoking, DM duration, cholesterol, LDLcholesterol, calcium channel blocker, thiazolidinedione, neuropathy, nephropathy, urine albumin creatinine ratio and CKD stage (all p<0.05).
Conclusion: Taken together, serum adiponectin level was significant relationship with hyperlipidemia, neuropathy and nephropathy. Our research showed that adiponectin was potential pharmacologic treatment modality of the diabetic complication of type 2 diabetic patients
|